Consolidated Statement Of Income

Kringle Pharma,Inc. - Filing #7338974

Concept 2023-10-01 to
2024-03-31
2022-10-01 to
2023-03-31
Consolidated statement of income
Statement of income
Net sales
43,029,000 JPY
34,353,000 JPY
Cost of sales
JPY
JPY
Operating expenses
Selling, general and administrative expenses
409,776,000 JPY
349,287,000 JPY
Operating expenses
Ordinary profit (loss)
-365,471,000 JPY
-314,811,000 JPY
Gross profit (loss)
43,029,000 JPY
34,353,000 JPY
Operating profit (loss)
-366,746,000 JPY
-314,934,000 JPY
Net sales
Operating expenses
Research and development expenses
293,788,000 JPY
231,712,000 JPY
Non-operating income
Interest income
7,000 JPY
5,000 JPY
Other
0 JPY
0 JPY
Non-operating income
1,275,000 JPY
188,000 JPY
Selling, general and administrative expenses
Cost of sales
Non-operating expenses
Non-operating expenses
JPY
65,000 JPY
Gross profit
Profit (loss) before income taxes
-365,471,000 JPY
-314,811,000 JPY
Income taxes - current
746,000 JPY
745,000 JPY
Income taxes
746,000 JPY
745,000 JPY
Profit (loss)
-366,217,000 JPY
-315,557,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.